临床试验：

2018年：海曲波帕治疗难治再障的多中心研究：中心PI

2018：法博进治疗初治MDS多中心研究：中心PI

2017：国际PNH登记研究（观察性研究）--PNH：中心PI

2017：羧基麦芽糖铁剂多中心三期临床试验—缺铁性贫血： 中心PI

2016：口服铁剂三期多中心临床试验—缺铁性贫血：中心PI

2015： 多中心多参数前瞻性评估免疫抑制治疗重型再障的疗效预测指标（观察性研究）-再生障碍性贫血：PI

2015：自体转化的脂肪造血干细胞治疗重型再生障碍性贫血—再生障碍性贫血（II期）： Co-PI

2015: MRI 检测输血依赖的再障、MDS患者铁过载治疗的疗效---MDS（观察性研究）： PI

2014:全国再生障碍性贫血的登记研究（观察性研究）--再生障碍性贫血  中心PI

2013:重型再生障碍性贫血的登记研究（观察性研究）--再生障碍性贫血  中心PI

2012： 诺华:MRI检测铁过载的多中心临床试验: 中心PI

2012:  Novartis: POMALIDOMIDE in anemia patientswith Myelofibrosis. Sub PI.

2011: Xiansheng, JiangsuPharm. Bendamustine HCL in newly diagnosed CLL patients. Sub PI.

2011: Alexoninternational PNH Registry, Co PI.

2011: Novartis:帕比司他联合硼替佐米和地塞米松治疗多发性骨髓瘤的国际多中心临床试验： Sub PI.

2009:Novartis PharmaStein AG: the survey of anemia patients with potential overload of iron.Principle Investigator (PI).

2008: Roche Pharmaceuticals Ltd: Maintenance therapy of Rituximab in patientswith complete remission DLBCL after 6-8 R-CHOP, PI

2008: Shanghai ZhongxinPharmaceuticals Ltd: CD20 monoclone antibody as the first line treatment inpatients with DLBCL. PI.

2007: Schering-PloughCorporation: DVD as the first line treatment of patients with multiple myeloma,participant. 

基金资助：

2020：三生TCP项目： 10万元。

2020: 白求恩基金会公益基金：15万元。

2020：中国医学科学院中央级公益性科研院所基本科研业务费专项（2019XK320047）

2019：中国医学科学院 临床转化项目

2018：北京市自然科学基金，项目编号：7192168

2016：中国医学科学院医学与健康科技创新工程，项目编号：2016-12M-3-004

2016：雷帕霉素治疗纯红再障的机制研究，中华医学会

2015：MRI在输血依赖再障、MDS患者随访中的意义中华医学会

2014： CHR在缺铁性贫血诊断中的意义  国家疾控中心

2014年  MRI监测输血依赖的再障、MDS患者铁过载的疗效 （中华医学会）

2014年 端粒及悬突结构在慢性粒细胞白血病中的研究 (中华医学会)

2013年，MRI检测MDS患者铁过载的研究，中华医学会基金

2010年： 国家自然科学基金： 端粒酶基因突变与骨髓增生异常综合征（PI）。

2009年：国家科技支撑计划：中国人营养代谢情况的调查分析---胃肠道肿瘤中贫血患者的流行病学调查及干预的研究部分。

2007年： 国际多中心PNH登记工作中国的主要研究者。

2006年： 人事部归国留学人员基金资助（第一作者，已完成）。

2005年：  北京协和医院院内科研基金资助二等奖（第一作者，已完成）。

国内外大会发言情况（近5年）：

1. 2019 美国及欧洲血液年会，大会海报发言

2. 2018 美国及欧洲血液年会，大会海报发言

3. 2018 韩国血液年会，大会口头发言（5篇）

4. 2018 日本血液学年会 大会发言

5. 2017 美国ASH poster presentation, travel awards

6. 2016 美国ASH poster presentation, travel awards

7. 2016日本血液学年会，poster presentation, travel awards.

8. 2016 全国血液学年会，大会发言2篇，poster 1篇

9. 北京血液学年会：大会发言

10. 2016 EHA poster presentation (2 篇)

11. 2015 全国红细胞疾病会议：大会发言及主持

12. 2015 EHA poster presentation

13. 2014 全国血液学大会口头发言（2篇）2002、2003年美国血液学年会（ASH）海报发言（第一作者）

14. 2012 EHA MDS与端粒及端粒悬突研究. POSTER presentation, travel award.

近10年发表论文（仅限第一作者及通讯作者，*标出）：

1. 陈婉淑，张梦露，韩冰. 骨髓增生异常综合征和急性髓细胞白血病的基因突变比较.中华血液学杂志，2021.42( 2)171-176.

2. Yuan Yang, Jiang Ji, Zengwei Tang, Bing Han. Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review. Front Oncol. 2021 Apr 26;11:614965.

3. Du Y, Han B. Advances in Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria.Transplant Cell Ther. 2021 Apr;27(4):301-307.

4. Fangfei Chen , Shimin Hu, Jing Ruan, Miao Chen Bing Han. Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. Blood Cancer J. 2021 Mar 16;11(3):58.

5. Wan Z, Han B. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies. Aging (Albany NY). 2021 Mar 26;13(8):11120-11134.

6. Ruan J, Han B, Zhuang J, Chen M, Chen F, Huang Y, Zhou W. Hereditary intrinsic factor deficiency in China caused by a novel mutation in the intrinsic factor gene-a case report. BMC Med Genet. 2020 Nov 10;21(1):221.

7. Ruan J, Han B. Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A. Chin Med J (Engl). 2021 Jan 19. 

8. Du Y, Yang C, Chen M, Ruan J, Huang Y, Chen F, Han B. Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a single-center retrospective study. Hematology. 2020 Dec;25(1):478-483. doi: 10.1080/16078454.2020.1852763. PMID: 33297889.

9. Du Y, Huang Y, Zhou W, Liu X, Chen F, Yang C, Chen M, Ruan J, Han B. Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study.Drug Des Devel Ther. 2020 Dec 30;14:5711-5719.

10. Yumei Liu, Chen Yang, Hua Xue, Fang Ye, Wanling Sun, Jingbo Wang, Weiwei Qi, Haiyue Niu, Luoming Hua, Huaquan Wang, Bing Han*, Zonghong Shao*. Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment. Int J Hematol. 2021 Mar 1. doi: 10.1007/s12185-021-03115-9. Online ahead of print.

11. Long Z, Li H, Du Y, Chen M, Zhuang J, Han B. Gene mutation profile in patients with acquired pure red cell aplasia. Ann Hematol. 2020 Aug;99(8):1749-1754.

12. Hui Di Zhang, Jie Cai, Meng Wu, Jie Ren, Ya Li Du, Zhang Biao Long , Guo Xun Li, Bing Han, Li Chen Yang .Verification of the Cut-off Value of the Reticulocyte Hemoglobin Content to Diagnose Iron Deficiency. Biomed Environ Sci. 2020 Jul 20;33(7):543-546.

13. Yuzhou Huang, Xianyong Jiang, Bing Han. Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report. Ther Adv Hematol. 2020 Jul 20;11:2040620720940144.

14. 姬姜,杜亚丽,阮菁,黄钰洲,韩冰.来那度胺治疗难治/复发骨髓增生异常综合征伴环形铁粒幼红细胞患者的效果分析[J]. 临床血液学杂志, 2020,33(05):614-617+624.

15. 韩冰，陈苗，杨辰，张连生. 中华医学会血液学分会红细胞疾病（贫血）学组. 中国卟啉病诊治专家共识（2020年) . 中华医学杂志,2020,100 (14): 1051-1056.

16. 韩冰，杨辰，陈苗，张连生. 中华医学会血液学分会红细胞疾病（贫血）学组.中国成人戈谢病诊治专家共识（2020）.中华医学杂志,2020,100(24):1841-184.

17. 北京协和医院罕见病多学科协作组.  韩冰，杨辰，陈苗，张抒扬. 戈谢病多学科诊疗专家共识(2020). 协和医学杂志.2020,1111(6):682-697.  

18. Hongmin Li, Jiang Ji, Yali Du, Yuzhou Huang, Hao Gu, Miao Chen, RunHui Wu, Bing Han. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Exp Hematol. 2020 Sep;89:87-95.

19. Ziqi Wan, Bing Han. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis. Front Oncol. 2020 Oct 7;10:579221.

20. 陈芳菲,郭智玮,张立男,杨辰,陈苗,叶芳,韩冰.52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究. 中华血液学杂志. 2020,41(10):806-810.

21. 张梦露,陈婉淑,韩冰.重组人血小板生成素对非重型再生障碍性贫血免疫抑制治疗疗效的影响.中华血液学杂志2020,41(8):637-642. 

22. Ruan J, Zuo W, Chen M, Yang C, Han B. Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.

Ann Hematol. 2020 Dec; 99(12):2755-2761. 

23. Chen Z, Chen M, Yang C, Han B.Immunosuppression therapy is effective for both acquired tumor-associated and primary pure red cell aplasia: a match pair case-control study. Ann Hematol. 2020 Jul;99(7):1485-1491.

24. Chen M, Zhuang J, Yang C, Zhang L, Wang W, Cai H, Yu Y, Li J, Zhou D, Han B. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol. 2020 May;99(5):1141-1143.

25. 张若曦，李红敏，伍洁，韩冰.检验血液参数在常见小细胞性贫血患者诊断鉴别的意义. 基础医学与临床. 2020 Jan.(40)1.105-109.

26. Jiang Ji , Miao Chen, Bing Han. Comparison of Hypomethylator Monotherapy With Hypomethylator Plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis. J Cancer 2020 Mar 4;11(10):2972-2980.

27. Chen Z, Liu X, Chen M, Yang C, Han B. Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency.Ann Hematol. 2020 Apr;99(4):737-741.

28. 韩冰. 我怎样治疗纯红再生障碍.中华血液学杂志. 2020 (1) 14;41(1):5-9.

29. 李红敏，张若曦，龙章彪，杜亚丽，陈苗，庄俊玲，邱正庆，韩冰. 酶替代治疗后22例I型戈谢病患者生活质量调查.中华血液学杂志.2020 Apr 14;41(4):287-29.

30. Geng C, Liu X, Chen M, Yang C1, Han B.Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia - A meta analysis.Leuk Res. 2020 Jan;88:106266.

31. Huang Y, Liu X, Chen F, Zhou W, Li H, Long Z, Yang C, Chen M, Han B. Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria.Ann Hematol. 2019 Oct;98(10):2283-2291.

32. Yang Z, Cui Q, Zhou W, Qiu L, Han B.Comparison of gene mutation spectrum of thalassemia in different regions of China and Southeast Asia.Mol Genet Genomic Med. 2019 Apr 9:e680.

33. Yang Z, Zhou W, Cui Q, Qiu L, Han B. Gene spectrum analysis of thalassemia for people residing in northern China. BMC Med Genet. 2019 May 22;20(1):86.

34. 高学慧，崔雀玄，张强兴，程歆琦，鲁军，邱玲，韩冰.健康查体人群内因子抗体阳性率和血清维生素B12缺乏率调查. 中华血液学杂志. 2018 Nov 14;39(11):917-920.

35. 杨辰，龙章彪，张炎，朱铁楠，韩冰.阵发性睡眠性血红蛋白尿症合并爆发性紫癜一例并文献复习. 中华血液学杂志，2018 Nov 14;39(11):921-926.

36. 李红敏，龙章彪，韩冰.铁稳态和铁相关性疾病.中华血液学杂志，2018，（9）14;39(9):790-792.

37. Long Z, Yu F, Du Y, Li H, Chen M, Zhuang J, Han B. Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus. Ann Hematol. Ann Hematol. 2018 Nov;97(11):2047-2054.

38. Long Z, Li H, Du Y, Han B.Congenital sideroblastic anemia: Advances in gene mutations and pathophysiology. Gene. 2018 Aug 20;668:182-189.

39. 陈苗, 庄俊玲, 段明辉, 张薇,李剑, 朱铁楠, 蔡华聪,曹欣欣,冯俊, 杨辰, 张炎, 张路, 周道斌, 韩冰.泊沙康唑初级预防重型再生障碍性贫血真菌感染的研究. 中华血液学杂志. 2018 Feb 14;39(2):128-131.

40. 杨辰，陈芳菲，龙章彪，杜亚丽，李红敏，陈苗，韩冰.西罗莫司对K562细胞及纯红再生障碍性贫血患者细胞体外生长的研究. 中华血液学杂志.2018 Apr 14;39(4):310-313.

41. Long Z, Du Y, Li H, Han B.CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. Gene. 2018 Jun 15;659:149-154.

42. Chen M, Ding C, Lu T, Niu N, Han B.Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus. Ann Hematol. 2018 Jan;97(1):189-192.

43. Chen M, Liu C, Qiao X, Zhou D, Zhuang J, Han B.Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia. Leuk Res. 2018 Jan 2;65:55-60.Long Z, Du Y, Li H, Han B.Polymorphism of the ABO gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. Oncotarget. 2017 Sep 28;8(54):92411-92419.

44. Li H, Wang L, Wu Y, Su L, Zhao H, Zhang Y, Wang Z, Huang D, Huang Z, Wu X, Li X, Ye F, Yu F, Liu H, Wang JW, Cong J, Sun W, Chen HR, Wang J, Han B. Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome. Acta Haematol. 2017 Oct 19;138(3):168-174.

45. Du Y, Long Z, Chen M, Han B, Hou B, Feng F. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. Acta Haematol. 2017;138(2):119-128.

46. 龙章彪，杜亚丽，韩冰.获得性铁粒幼细胞性贫血的研究进展.中华血液学杂志.2017 Jan 14;38(1):83-86.

47. 龙章彪，杜亚丽，韩冰. 先天性铁粒幼细胞性贫血的基因突变和发病机制研究进展.中华血液学杂志.2016 Dec 14;37(12):1090-1093.

48. Chen M, Zhuang J, Zhou D, Xu Y, Zhao Y, Wang S, Zhang W, Duan M, Zhu T, Li J, Cai H, Cao X, Han B. Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection. Ann Hematol. 2017 Apr;96(4):581-587.

49. Yongwei Wang, Yali Du, Gang Liu, Shanshan Guo, Na Yang, Bo Hou, Xianyong Jiang ,Bing Han, Yanzhong Chang, Guangjun Nie: Contiguous gene deletion in HFE2 region (1q21.1) and pathogenic HFE2 mutations in a Chinese hereditary hemochromatosis patient. Gene Reports 2016:167-170.

50. Wang Y, Du Y, Liu G, Guo S, Hou B, Jiang X, Han B, Chang Y, Nie G. Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis. Int J Hematol. 2017 Apr;105(4):521-525.

51. Long ZB, Wang YW, Yang C, Liu G, Du YL, Nie GJ, Chang YZ, Han B. Identification of FECH gene multiple variations in two Chinese patients with erythropoietic protoporphyria and a review. J Zhejiang Univ Sci B. 2016 Oct;17(10):813-820.

52. 杜亚丽，龙章彪，韩冰：阵发性睡眠性血红蛋白尿症与血栓发生的研究进展；基础医学与临床.2017;37:128-132.

53. Du Y, Zhang Q, Han B. Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol. 2016 Aug;38(4):e84-85.

54. 杜亚丽，龙章彪，庄俊玲，谢海雁，韩冰.阵发性睡眠性血红蛋白尿症血栓的初步研究.中华血液学杂志. 2016 Apr;37(4):318-323.

55. Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016 Jun;103(6):649-654.

56. Chen M, Liu C, Zhuang J, Zou N, Xu Y, Zhang W, Li J, Duan M, Zhu T, Cai H, Cao X, Wang S, Zhou D, Han B. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. Eur J Haematol. 2016 Mar;96(3):291-296.